AUTHOR INDEX

Volume 62 • 1993

Abe, Y. *See* Tamaki, T.
Aihara, K. *See* Yamaguchi, T.
Aki, Y. *See* Tamaki, T.
Akiyama, Y., Hara, K., Ohkawa, I. and Tajima, T.
Effect of menatetrenone on bone loss 145
Ando, H. *See* Takeya, K.
Ando, S. *See* Takeya, K.
Aniya, Y. and Daido, A.
Activation of glutathione *S*-transferase 9
Ano, M. *See* Ono, S.
Arcadi, F.A. *See* Trimarchi, G.R.
Asakawa, T. *See* Enomoto, K.

Baba, T. *See* Zhang, X.-Q.
Beppu, Y. *See* Shuto, K.

Chiba, S. *See* Nakane, T.
Chiyotani, A. *See* Tamaoki, J.
Costa, G. *See* Trimarchi, G.R.

Daido, A. *See* Aniya, Y.
De Luca, R. *See* Trimarchi, G.R.
Dohi, T. *See* Endo, K.

Ebihara, A. *See* Fujimura, A.
Endo, K., Morita, K., Uchiyama, Y., Takada, K., Tsujimoto, A. and Dohi, T.
Serotonin and lidocaine convulsions 325
Enomoto, K., Hayama, K., Takano, M. and Asakawa, T.
Inhibition of adenylate cyclase activity 103

Fujimori, K. *See* Taguchi, T.
Fujimura, A., Shiga, T., Sudoh, T., Ohashi, K. and Ebihara, A.
Chronopharmacology of furosemide 403
Fujiwara, M. *See* Kunitomo, M.
Fukuda, H. *See* Ono, H.
Fukushima, C. *See* Ono, H.
Fukushima, T. *See* Ito, Yutaka
Funada, M. *See* Narita, M.

Ginkawa, M. *See* Kontani, H.
Gomi, Y. *See* Iwanaga, Y.
Goshima, Y. *See* Nakamura, Shinichi
—— *See* Sato, K.

Hagihara, A. *See* Saito, Tadayuki
Haji, A. *See* Takeda, R.
Hara, K. *See* Akiyama, Y.
Hasui, K. *See* Tamaki, T.
Hata, F. *See* Suthamnatpong, N.
Hattori, K. *See* Shikimi, T.
Hayama, K. *See* Enomoto, K.
Hiraga, Y. *See* Miura, N.
Hirata, K. *See* Ono, S.
Hirose, A. *See* Maruoka, Y.
Honda, Kazuo *See* Yazawa, H.
Honda, Kenji, Takano, Y. and Kamiya, H.
Muscarinic receptor of smooth muscle 43
Horiba, M. *See* Kohno, S.
Hsu, K.-S., Kang, J.-J. and Lin-Shiau, S.-Y.
Effects of As^{3+} on phrenic nerve-diaphragm 161

Igarashi, N. *See* Saito, Tadayuki
Iida-Kubota, E. *See* Yazawa, H.
Ikeda, Y. *See* Miura, N.
Imai, S. *See* Kawada, T.
Imaizumi, N. *See* Kunitomo, M.
Imperatore, C. *See* Trimarchi, G.R.
Inoue, K. *See* Okabe, S.
Ishida, Y. *See* Shuto, K.
Ishihara, H. *See* Okunishi, H.
Ishikawa, M., Ozaki, M., Takayanagi, Y. and Sasaki, K.
Systemic anaphylaxis and hepatic MFO 407
Isono, T., Sato, N., Koibuchi, Y., Sakai, S., Yamamoto, T., Ozaki, R., Mori, J., Kohsaka, M. and Ohtsuka, M.
Myocardial ischemia and FK409 315
Ito, K. *See* Saito, Tadayuki
Ito, Yasuo *See* Iwanaga, Y.
Ito, Yutaka, Nakamura, Susumu, Onoda, Y., Sugawara, Y. and Takaiti, O.
Inactivation of pepsin by ecabet 169
Ito, Yutaka, Onoda, Y., Nakamura, Susumu, Tagawa, K., Fukushima, T., Sugawara, Y. and Takaiti, O.
Protection from pepsin by ecabet 175
Iwanaga, Y., Suzuki, N., Kato, K., Kimura, T., Morikawa, K., Kato, Hideo, Ito, Yasuo and Gomi, Y.
HSR-803-induced ileal peristalsis 395
Iwasaki, T. *See* Miura, N.
Izawa, T. *See* Komabayashi, T.

Kamiya, H. *See* Honda, Kenji
Kanada, A. *See* Suthamnatpong, N.
Kanemura, T. *See* Tamaoki, J.
Kang, J.-J. *See* Hsu, K.-S.
Karasawa, Y. and Koss, M.C.
α-Adrenoceptors in cat paw vasculature 211
Kato, Hideo *See* Iwanaga, Y.
Kato, Hitoshi *See* Takata, Y.
Kato, K. *See* Iwanaga, Y.
Kato, T. *See* Maruoka, Y.
Kawada, T., Sun, H.-T., Nakazawa, M. and Imai, S.
Ca^{2+}-antagonistic actions of lacidipine 289
Kawai, K. *See* Nakane, T.
Kawamoto, T. *See* Okunishi, H.
Kimura, I., Okazaki, M. and Kimura, M.
ACh release in diabetic neuromuscular junction 35
Kimura, M. *See* Kimura, I.
Kimura, S. *See* Tamaki, T.
Kimura, T. *See* Iwanaga, Y.
Kitahara, M. *See* Sakashita, M.
Kitamura, K. *See* Ono, S.
Kobayashi, T. *See* Okunishi, H.
Kogi, K. *See* Yamaguchi, T.
Kohno, S., Ogawa, K., Nabe, T., Yamamura, H. and Ohata, K.
Modulation of histamine release 75
Kohno, S., Tsuzuike, N., Yamamura, H., Nabe, T., Horiba, M. and Ohata, K.
Role of p-LTs in bronchial resting tonus 351
Kohsaka, M. *See* Isono, T.
Koibuchi, Y. *See* Isono, T.

Komabayashi, T., Noguchi, M., Izawa, T., Suda, K. and Tsuboi, M.
Isoprenaline-stimulated DAG formation 379
Konno, K. *See* Tamaoki, J.
Kontani, H., Ginkawa, M. and Sakai, T.
Drug on ureteral peristaltic pressure 331
Koss, M.C. *See* Karasawa, Y.
Kunihara, M., Ohyama, M. and Nakano, M.
Dopamine system for spiradoline actions 223
Kunitomo, M., Imaizumi, N., Sameshima, E. and Fujiwara, M.
Tachykinin receptors in rabbit iris 257
Kuribara, H. and Uchihashi, Y.
CNS stimulation and dopamine antagonists 111
Kuribara, H. *See* Saito, Takashi

Lin-Shiau, S.-Y. *See* Hsu, K.-S.

Maehara, T. *See* Suthamnatpong, N.
Maekawa, M. *See* Ono, S.
Maruoka, Y., Ohno, Y., Kato, T., Hirose, A., Tatsuno, T. and Nakamura, M.
Effects of SM-9018 on monoamines in rats 419
Maruyama, K., Ohkura, N., Yagi, Y. and Nagatomo, T.
α_1-Adrenoceptor subtypes in aorta 263
Matsuda, N. *See* Saito, Tadayuki
Matsuda, T. *See* Mori, M.
Matsuki, N., Sakuma, Y. and Saito, H.
Cardiovascular properties of suncus 93
Matsumoto, K. *See* Ohta, H.
Mio, M. *See* Saito, Tadayuki
Misawa, M. *See* Narita, M.
Misu, Y. *See* Nakamura, Shinichi
—— *See* Sato, K.
Miura, N., Nakata, N., Tanaka, Y., Hiraga, Y., Ikeda, Y., Ohata, H. and Iwasaki, T.
Effects of FG-7080 on memory tasks 203
Miyake, K. *See* Taguchi, T.
Miyamae, T. *See* Nakamura, Shinichi
—— *See* Sato, K.
Miyazaki, M. *See* Okunishi, H.
Mori, J. *See* Isono, T.
Mori, M., Tsushima, H. and Matsuda, T.
Effect of SP in the SON 49
Mori, N. *See* Okunishi, H.
Morikawa, K. *See* Iwanaga, Y.
Morita, K. *See* Endo, K.

Nabe, T. *See* Kohno, S.
Nagase, H. *See* Narita, M.
Nagata, M. and Osumi, Y.
Central α_2-adrenoceptor and gastric motility 329
Nagatomo, T. *See* Maruyama, K.
Nakamura, K. *See* Ohoi, I.
Nakamura, M. *See* Maruoka, Y.
Nakamura, Shinichi, Goshima, Y., Yue, J.-L., Miyamae, T. and Misu, Y.
DOPA and locomotor activity by nicotine 107
Nakamura, Susumu *See* Ito, Yutaka
Nakane, T., Kawai, K. and Chiba, S.
Pindolol-induced coronary vasoconstriction 67
Nakano, M. *See* Kunihara, M.
Nakano, S. *See* Song, J.G.
Nakata, N. *See* Miura, N.
Nakayama, S. *See* Sakashita, M.
Nakazawa, M. *See* Kawada, T.
Narita, H. *See* Ono, S.
Narita, M., Takahashi, Y., Takamori, K., Funada, M., Suzuki, T., Misawa, M. and Nagase, H.
Interaction between μ- and κ-agonists 15
Narita, S. *See* Yamaguchi, T.
Noguchi, M. *See* Komabayashi, T.
Nomura, H. *See* Takeya, K.
Nose, T. and Tsurumi, K.
Quantification of ultraviolet erythema 245

Ogawa, K. *See* Kohno, S.
Ogawa, N. *See* Song, J.G.
Oguchi, K. *See* Sakashita, M.
Ohashi, K. *See* Fujimura, A.
Ohata, H. *See* Miura, N.
Ohata, K. *See* Kohno, S.
Ohdo, S. *See* Song, J.G.
Ohkawa, I. *See* Akiyama, Y.
Ohkura, N. *See* Maruyama, K.
Ohnishi, M. *See* Zhang, X.-Q.
Ohno, Y. *See* Maruoka, Y.
Ohoi, I., Tobari, H. and Nakamura, K.
Measurement of oxy-radicals 415
Ohta, H., Matsumoto, K., Watanabe, H. and Shimizu, M.
Paeoniflorin and α_1-adrenergic systems 199
Paeoniflorin and β-adrenergic systems 345
Ohtsuka, M. *See* Isono, T.
Ohyama, M. *See* Kunihara, M.
Oka, Y. *See* Okunishi, H.
Okabe, E. *See* Sasaki, H.
Okabe, S., Takagi, K. and Inoue, K.
NC-1300-O-3, a new antiulcer drug 25
Okada, M. *See* Taguchi, T.
Okazaki, M. *See* Kimura, I.
Okumura, F. *See* Sato, K.
Okunishi, H., Oka, Y., Shiota, N., Kawamoto, T., Song, K. and Miyazaki, M.
Vascular angiotensin II formation 207
Okunishi, H., Song, K., Oka, Y., Kobayashi, T., Kawamoto, T., Ishihara, H., Mori, N. and Miyazaki, M.
A novel angiotensin II antagonist 239
Ono, H., Fukushima, C. and Fukuda, H.
Tizanidine on spinal reflexes 357
Ono, S., Kitamura, K., Maekawa, M., Hirata, K., Ano, M., Ukai, W., Yamafuji, T. and Narita, H.
Anti-anoxic actions of T-588 81
Onoda, Y. *See* Ito, Yutaka
Osumi, Y. *See* Nagata, M.
Ozaki, M. *See* Ishikawa, M.
Ozaki, R. *See* Isono, T.

Saida, K. *See* Umeda, M.
Saito, H. *See* Matsuki, N.
Saito, Tadayuki, Hagihara, A., Igarashi, N., Matsuda, N., Yamashita, A., Ito, K., Mio, M. and Tasaka, K.
Effect of emedastine on histamine release 137
Saito, Takashi, Shuto, K., Kuribara, H. and Tadokoro, S.
Behavioral effects of OM-853 183
Saito, Takashi *See* Shuto, K.
Sakai, N. *See* Tamaoki, J.
Sakai, S. *See* Isono, T.
Sakai, T. *See* Kontani, H.
Sakashita, M., Toyoda, K., Kitahara, M., Tsuruzoe, N., Nakayama, S. and Oguchi, K.
Mechanisms of hypolipidemic effect of NIP-200 87
Sakitama, K.
Intrathecal noradrenaline on flexor reflex 131

Sakuma, Y. *See* Matsuki, N.
Sameshima, E. *See* Kunitomo, M.
Santoro, G. *See* Trimarchi, G.R.
Sasaki, H. and Okabe, E.
$^{\bullet}$OH radical and vascular reactivity 305
Sasaki, K. *See* Ishikawa, M.
Sato, K., Okumura, F., Goshima, Y., Miyamae, T. and Misu, Y.
DOPA potentiates presynaptic α_2-activity 119
Sato, N. *See* Isono, T.
Shibuya, T. *See* Zhang, X.-Q.
Shiga, T. *See* Fujimura, A.
Shikimi, T., Hattori, K. and Takaori, S.
Heparin on ulinastatin activity 115
Shimada, F. *See* Takata, Y.
Shimizu, M. *See* Ohta, H.
Shiota, N. *See* Okunishi, H.
Shuto, K. *See* Saito, Takashi
Shuto, K., Saito, Takashi, Beppu, Y. and Ishida, Y.
OM-853 on behavioral responses in rats 99
Song, J.G., Nakano, S., Ohdo, S. and Ogawa, N.
Chronotoxicity of methotrexate 373
Song, K. *See* Okunishi, H.
Suda, K. *See* Komabayashi, T.
Sudoh, T. *See* Fujimura, A.
Sugawara, Y. *See* Ito, Yutaka
Sun, H.-T. *See* Kawada, T.
Suthamnatpong, N., Maehara, T., Kanada, A., Takeuchi, T. and Hata, F.
Cyclic GMP and relaxation of rat colon 387
Suzuki, N. *See* Iwanaga, Y.
Suzuki, T. *See* Narita, M.

Tadokoro, S. *See* Saito, Takashi
Tagawa, K. *See* Ito, Yutaka
Taguchi, T., Miyake, K., Tanonaka, K., Okada, M., Takagi, N., Fujimori, K. and Takeo, S.
Neurotransmitters in brain ischemia 269
Tajima, T. *See* Akiyama, Y.
Takada, K. *See* Endo, K.
Takagi, K. *See* Okabe, S.
Takagi, N. *See* Taguchi, T.
Takahashi, Y. *See* Narita, M.
Takaiti, O. *See* Ito, Yutaka
Takamori, K. *See* Narita, M.
Takano, M. *See* Enomoto, K.
Takano, Y. *See* Honda, Kenji
Takaori, S. *See* Shikimi, T.
Takata, Y., Shimada, F. and Kato, Hitoshi
Hypoxic decrease in NE release 279
Takayanagi, Y. *See* Ishikawa, M.
Takeda, R. and Haji, A.
Isoflurane on respiratory neuron 57
Takeo, S. *See* Taguchi, T.
Takeuchi, T. *See* Suthamnatpong, N.
Takeya, K., Ando, H., Ando, S., Yajima, M. and Nomura, H.
Effect of vesnarinone on the trachea 191
Takeyama, K. *See* Tamaoki, J.
Tamaki, T., Hasui, K., Aki, Y., Kimura, S. and Abe, Y.
L-NNA and afferent arteriole 231
Tamaoki, J., Chiyotani, A., Takeyama, K., Kanemura, T., Sakai, N. and Konno, K.
Kampo drugs potentiate β-adrenoceptors 155
Tanaka, Y. *See* Miura, N.
Tanonaka, K. *See* Taguchi, T.
Tasaka, K. *See* Saito, Tadayuki
Tatsuno, T. *See* Maruoka, Y.
Tobari, H. *See* Ohoi, I.
Toyoda, K. *See* Sakashita, M.
Trimarchi, F. *See* Trimarchi, G.R.
Trimarchi, G.R., Arcadi, F.A., De Luca, R., Imperatore, C., Santoro, G., Trimarchi, F. and Costa, G.
Neuroprotective activity of FBP in gerbils 215
Tsuboi, M. *See* Komabayashi, T.
Tsujimoto, A. *See* Endo, K.
Tsurumi, K. *See* Nose, T.
Tsuruzoe, N. *See* Sakashita, M.
Tsushima, H. *See* Mori, M.
Tsuzuike, N. *See* Kohno, S.

Uchida, M., Yano, S. and Watanabe, K.
Effect of capsaicin on gastroprotection 123
Uchihashi, Y. *See* Kuribara, H.
Uchiyama, Y. *See* Endo, K.
Ukai, W. *See* Ono, S.
Umeda, M. and Saida, K.
Cardioprotective effect of nisoldipine 1

Watanabe, H. *See* Ohta, H.
Watanabe, K. *See* Uchida, M.
Watanabe, Y. *See* Zhang, X.-Q.

Yagi, Y. *See* Maruyama, K.
Yajima, M. *See* Takeya, K.
Yamada, S. *See* Yamaguchi, T.
Yamafuji, T. *See* Ono, S.
Yamaguchi, T., Aihara, K., Yamada, S., Narita, S. and Kogi, K.
A new proton pump inhibitor, TY-11345 363
Yamamoto, T. *See* Isono, T.
Yamamura, H. *See* Kohno, S.
Yamashita, A. *See* Saito, Tadayuki
Yano, S. *See* Uchida, M.
Yazawa, H., Iida-Kubota, E. and Honda, Kazuo
Angiotensin II receptor in HASMCs 339
Yazawa, H. and Honda, Kazuo
α_1-Adrenoceptor subtype in rat prostate 297
Yue, J.-L. *See* Nakamura, Shinichi

Zhang, X.-Q., Watanabe, Y., Ohnishi, M., Baba, T. and Shibuya, T.
Inhibition by Ca antagonists in CNS 411

SUBJECT INDEX

Volume 62 • 1993

Acetylcholine 269
[^{3}H]Acetylcholine release 35, 395
Active avoidance 183
Adenylate cyclase 103
α_1-Adrenergic system 199
α_1-Adrenoceptor 131, 263
α_2-Adrenoceptor 119, 131
β-Adrenoceptor 155
α-Adrenoceptor subtype 211
α_1-Adrenoceptor subtype 297
Afferent arteriole (isolated) 231
Afferent fiber (Group II) 131
Airway smooth muscle 155
Ambulatory activity 183
Amino acid 269
Amygdala 99
Analgesia 223
Angiotensin II 339
Angiotensin II-receptor antagonist (non-peptide) 239
Antagonist 351
Anti-anoxic action 81
Antidiuresis 49
Anti-inflammatory drug 245
Antinociception 15
Anti-pepsin activity 169
Antisecretory effect 363
Antiulcer effect 363
Aorta (canine) 263
Aorta (human) 339
L-Arginine 231
Arsenite 161
Asthma 155
Atenolol 345
ATP content 279
ATP-sensitive K^+ channel 279
Autoradiography (in vitro) 239

Bakumondo-to 155
Blood flow 123
Blood flow change 245
Blood pressure 357
Blood pressure control 93
Bone loss 145
BRL 38227 ((−)6-cyano-3,4-dihydro-2,2-dimethyl-*trans*-4-(2-oxo-1-pyrrolidyl)-2*H*-1-benzopyran-3-ol) 331
Bronchi 351
t-Butyl hydroperoxide 9

Calcitonin gene-related peptide (CGRP) 123
Calcium antagonist 411
Calmodulin 103
Capsaicin-sensitive nerve 123
Captopril 207
Cardiac muscle 289
Central adrenergic neurotransmission 279
Central α_2-adrenoceptor 329
Cerebellar granule cell (cultured) 411
Cerebral activator 81
Cerebral ischemia (transient, gerbil) 215
Chemiluminescence 415
Cholesterol 87
Choline 269
Cholinergic function 81
Chronopharmacokinetics 373
Chronopharmacology 403
Chronotoxicity 373
Chymase 207
Chymostatin 207
Circadian rhythm 373
Colonic motility 387
Convulsion 325
Coronary artery 67, 315
Coronary vasodilating action 1
Cumene hydroperoxide 9
Cyclic AMP 191
Cyclic GMP 387

Diacylglycerol formation 379
Diaphragm (mouse) 161
Dimaprit 75
Discrete shuttle avoidance 111
DOPA (endogenous neuroactive substance) 107, 119
Dopamine D_1- and D_2-antagonists 111
Dopaminergic system 223
Doxazosin 403

Ecabet (TA-2711, (+)-(1*R*,4a*S*,10a*R*)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate) 169, 175
Electron spin resonance 305
Emedastine difumarate 137
Endothelium 305
Endothelium-derived relaxing factor 231
Enzyme activation 9

Feeding schedule 373
FK409 ((±)-(*E*)-4-ethyl-2-[(*E*)-hydroxyimino]-5-nitro-3-hexenamide) 315
Flexor reflex 131
Fructose-1,6-bisphosphate 215
Furosemide 403

G protein $\beta\gamma$-subunit 103
Gastric motility 329
Gastric secretion 25
Glibenclamide 331
Glutathione transferase (liver microsome) 9

H^+/K^+-ATPase inhibitor 363
Heart (rabbit, perfused) 1
Heparin 115
Hepatic drug-metabolizing activity 407
Histamine 75
Histamine release 137
Hog pepsin 169
Hog pepsinogen 169
HSR-803 (*N*-[4-[2-(dimethylamino)ethoxy]-benzyl]-3,4-dimethoxybenzamide hydrochloride) 395
7α-Hydroxylase activity 87
5-Hydroxytryptamine 67
Hypolipidemic effect 87
Hypoxia 279

Ileum (guinea pig) 43, 395
Immobility 99
Indomethacin 25
Inflammation (cutaneous) 245
Input resistance 57
Intracellular Ca^{2+} 137
Iris (rabbit) 257
Ischemia (brain) 269
Ischemia (forebrain) 183
Ischemia (heart) 415
Ischemic myocardial function 1
Isoflurane 57
Isoprenaline 379

Ketanserin 67

Lacidipine 289
Learning and memory 203
Leukotriene 351
Lidocaine 325, 331
Lingual artery 305
Linoleic acid hydroperoxide 9
5-Lipoxygenase 351
Locomotion 15
Locomotor activity 223
Losartan 239

Mast cell 75, 137
Menatetrenone 145
Methotrexate 373
α-Methyl-*p*-tyrosine 107
(*R*)-α-Methylhistamine 75
Microsphere-embolism 269
Monoamine 419
Morphine 15
Mucus 123
Muscarinic antagonist 43
Muscarinic M_3 subtype 43
Muscle contracture 161
Muscle relaxant 357
Myocardial ischemia 315

NC-1300-O-3 (2-[2-*N*-methyl-*N*-(2-methylpropyl)amino]benzylsulfinyl benzimidazole) 25
Neurokinin A 257
Neuroleptic 419
Neuronal death (delayed) 215
Nicotine (increase in locomotor activity) 107
Nicotinic acetylcholine receptor (presynaptic) 35

Nifedipine 289, 331
NIP-200 (3,5-dimethyl-4,6-diphenyl-tetrahydro-2*H*-1,3,5-thiadiazine-2-thione) 87
Nisoldipine 1
N^G-Nitro-L-arginine 231
Nitric oxide (NO) 231, 315, 387
NK_1-receptor 257
Nonadrenergic, noncholinergic (NANC) inhibition 387
Noradrenaline 131
Noradrenaline release (rat hypothalamic slices) 119
Noradrenergic 357

OM-853 ((±)-methyl 3-ethyl-2,3,3a,4-tetrahydro-1*H*-indolo[3,2,1-de][1,5]naphthyridine-6-carboxylate monohydrochloride, vinconate hydrochloride) 99, 183
Omeprazole 363
Opioid interaction 15
κ-Opioid-receptor agonist 223
Organ selectivity 289
Ovariectomy 145
Oxygen free radical 305
Oxygen radical 415

Paeoniflorin 199, 345
Parotid acinar cell 379
Passive avoidance 183
Peptic hydrolysis 175
Peristalsis 395
Phosphoinositide hydrolysis 379
Phosphoinositide response 43
Phrenic nerve-diaphragm muscle (mouse) 35
Pindolol 67
Postsynaptic potential 57
^{3}H-Prazosin 263
Propranolol 345
Prostate (rat) 297
Protein binding 175

[^{3}H]Quinuclidinyl benzilate binding 395

Radial maze 199, 345
$^{86}Rb^+$ efflux 279
Receptor 339
Receptor operated Ca^{2+} channel 411
Receptor subtype 239
Respiratory neuron 57
Resting tonus 351

Saiboku-to 155
Scopolamine 203, 345
Serotonin 325
Serotonin reuptake inhibitor 203
Skin colorimetry 245
SM-9018 (*cis*-2-(4-(4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-1*H*-isoindole-1,3(2*H*)-dione HCl) 419
Smooth muscle cell 339
Species-dependent difference 93
Spinal reflex 357
Spiradoline 223
Stimulant 111
Straub tail 15
Streptozocin-diabetes 35
Substance P 49, 137, 257
Substance P antagonist 49
Succinylcholine 35
Suncus 93
Supraoptic nucleus 49
Sympathetic nerve stimulation 211
Systemic anaphylaxis (rat) 407

T-588 (*R*(−)-1-(benzo[*b*]thiophen-5-yl)-2-[2-(*N,N*-diethylamino)ethoxy]ethanol hydrochloride) 81
Tachykinin antagonist (selective) 257
Tacrine 81
Tetrodotoxin 57
Thioperamide 75
Tizanidine 357
Tracheal muscle 191
Twitch blockade 161
TY-11345 ((±)-2-[(4-methoxy-6,7,8,9-tetrahydro-5*H*-cyclohepta[*b*]pyridin-9-yl)-sulfinyl]-1*H*-benzimidazole sodium salt) 363

Ulcer (acetic acid-induced) 25
Ulcer healing 25
Ulinastatin 115
Ultraviolet erythema 245
Ureteral peristaltic function (rat) 331
Urinary trypsin inhibitor (human) 115

Vagus reflex 93
Vascular smooth muscle 289, 305
Vasoactive intestinal peptide (VIP) 387
Vasoconstriction 67
Vasoconstrictor response (cat paw) 211
Vasodilation 315
Vasopressin 49
Vesnarinone 191